Stock Scorecard
Stock Summary for Cidara Therapeutics Inc (CDTX) - $48.78 as of 7/3/2025 9:04:40 PM EST
Total Score
8 out of 30
Safety Score
41 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for CDTX
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for CDTX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for CDTX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for CDTX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for CDTX (41 out of 100)
| Stock Price Rating (Max of 10) | 8 |
| Historical Stock Price Rating (Max of 10) | 7 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 5 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 3 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 5 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for CDTX
Financial Details for CDTX
Company Overview |
|
|---|---|
| Ticker | CDTX |
| Company Name | Cidara Therapeutics Inc |
| Country | USA |
| Description | Cidara Therapeutics, Inc., a biotechnology company, is focused on the discovery, development, and commercialization of new long-acting anti-infectives for the treatment and prevention of disease in the United States. The company is headquartered in San Diego, California. |
| Sector Name | LIFE SCIENCES |
| Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| Most Recent Quarter | 3/31/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 48.78 |
| Price 4 Years Ago | 25.40 |
| Last Day Price Updated | 7/3/2025 9:04:40 PM EST |
| Last Day Volume | 412,729 |
| Average Daily Volume | 908,340 |
| 52-Week High | 56.83 |
| 52-Week Low | 10.14 |
| Last Price to 52 Week Low | 381.07% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 58.65 |
| Sector PE | 40.90 |
| 5-Year Average PE | -28.36 |
| Free Cash Flow Ratio | 6.07 |
| Industry Free Cash Flow Ratio | 19.40 |
| Sector Free Cash Flow Ratio | 32.91 |
| Current Ratio Most Recent Quarter | 3.87 |
| Total Cash Per Share | 8.04 |
| Book Value Per Share Most Recent Quarter | 11.61 |
| Price to Book Ratio | 7.06 |
| Industry Price to Book Ratio | 18.75 |
| Sector Price to Book Ratio | 30.76 |
| Price to Sales Ratio Twelve Trailing Months | 3,316.72 |
| Industry Price to Sales Ratio Twelve Trailing Months | 48.40 |
| Sector Price to Sales Ratio Twelve Trailing Months | 35.60 |
| Analyst Buy Ratings | 2 |
| Analyst Strong Buy Ratings | 3 |
Share Statistics |
|
| Total Shares Outstanding | 20,924,400 |
| Market Capitalization | 1,020,692,232 |
| Institutional Ownership | 55.45% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -640.60% |
| Reported EPS 12 Trailing Months | -26.68 |
| Reported EPS Past Year | -1.66 |
| Reported EPS Prior Year | -30.10 |
| Net Income Twelve Trailing Months | -180,732,000 |
| Net Income Past Year | -169,827,000 |
| Net Income Prior Year | -22,931,000 |
| Quarterly Revenue Growth YOY | -100.00% |
| 5-Year Revenue Growth | -42.85% |
| Operating Margin Twelve Trailing Months | -35,744.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 168,150,000 |
| Total Cash Past Year | 189,825,000 |
| Total Cash Prior Year | 35,778,000 |
| Net Cash Position Most Recent Quarter | 167,780,000 |
| Net Cash Position Past Year | 187,234,000 |
| Long Term Debt Past Year | 2,591,000 |
| Long Term Debt Prior Year | 2,591,000 |
| Total Debt Most Recent Quarter | 370,000 |
| Equity to Debt Ratio Past Year | 0.98 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 163,308,000 |
| Total Stockholder Equity Prior Year | -8,210,000 |
| Total Stockholder Equity Most Recent Quarter | 141,682,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -191,945,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -9.17 |
| Free Cash Flow Past Year | -176,662,000 |
| Free Cash Flow Prior Year | -22,937,000 |
Options |
|
| Put/Call Ratio | 1.67 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 6.36 |
| MACD Signal | 3.82 |
| 20-Day Bollinger Lower Band | 7.62 |
| 20-Day Bollinger Middle Band | 24.58 |
| 20-Day Bollinger Upper Band | 41.54 |
| Beta | 0.80 |
| RSI | 71.76 |
| 50-Day SMA | 19.36 |
| 150-Day SMA | 18.27 |
| 200-Day SMA | 19.06 |
System |
|
| Modified | 7/4/2025 3:27:07 AM EST |